It’s all thanks to a cross-linking procedure that has been introduced at Musgrove Park Hospital to treat patients with ...

Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.

Glaukos (GKOS) announced it has received the “Day 74” notification from the U.S. Food and Drug Administration FDA acknowledging the previously ...

There is a synergistic effect in the combination of ICRS and CXL treatment. Deep anterior lamellar keratoplasty improves the safety of corneal transplantation. However, this procedure is still ...

We evaluated Intacs efficiency according to different keratoconus stages. [19] In this retrospective noncomparative case series, 306 keratoconic eyes of 255 patients who had Intacs segment ...

Conventional keratoconus treatments such as eyeglasses or contact lenses address symptoms but Glaukos’ first-generation iLink therapy, known as Photrexa ®, or Epi-off, is the first and only FDA ...

Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it ...

Patients in Somerset with a "debilitating" condition that causes blurred vision can now access treatment that prevents progression of the condition. Keratoconus, which causes the cornea to thin ...

Centre for Sight offers AI-driven LASIK laser surgery technology for precise vision correction in under ten seconds per eye.